A. Joshi

发表

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Sourav K. Mishra, J. Sancho, R. Bouabdallah, 2020, The Lancet. Haematology.

Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.

G. Stone, S. Ellis, D. Baim, 2010, JACC. Cardiovascular interventions.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.

I. Vergote, N. Concin, M. Mirza, 2019, Gynecologic oncology.

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Mariano J. Alvarez, H. Döhner, A. Califano, 2021, Leukemia & lymphoma.

TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions.

A. Colombo, G. Guagliumi, S. Mascioli, 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.

J. Fajadet, I. Meredith, K. Oldroyd, 2012, Journal of the American College of Cardiology.

Everolimus-eluting stents: update on current clinical studies

K. Dawkins, D. Allocco, A. Joshi, 2011, Medical devices.

Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients

G. Stone, S. Ellis, D. Baim, 2009, Circulation. Cardiovascular interventions.

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2020, EJHaem.

Primary Endpoint Results of the EVOLVE Trial Drug-eluting stents delivering antiproliferative drugs from a durable polymer

J. Fajadet, K. Oldroyd, O. Varenne, 2012 .

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents.

G. Stone, Hong Wang, S. Ellis, 2013, Journal of interventional cardiology.

A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sourav K. Mishra, J. Sancho, R. Bouabdallah, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.

G. Stone, S. Ellis, D. Baim, 2010, JACC. Cardiovascular interventions.

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.